补充免疫抑制疗法可能有利于一些患有原发性胆道胆炎和自身免疫现象的患者
Mengqi Li1,2,3, Sha Chen1,2,3, Shuxiang Li1,2,3
1Liver Research Center, Beijing Friendship Hospital, Capital Medical University, Beijing, China.
Therapeutic advances in gastroenterology
|January 22, 2024
概括
在初级胆道胆炎 (PBC) 患者中,在ursodeoxycholic acid (UDCA) 添加免疫抑制疗法时,转氨酶和免疫球蛋白G (IgG) 的水平升高,改善了生物化学反应率. 这种疗法还提高了特定亚组的无移植生存率,这些亚组具有更高的酶或IgG水平.
科学领域:
- 肝病学 肝病学是一种肝病学.
- 免疫学 免疫学 免疫学
- 临床医学 临床医学
背景情况:
- 轻微升高的透氨酶和免疫球蛋白G (IgG) 水平在一次性胆道胆炎 (PBC) 中很常见.
- 在没有自身免疫性肝炎 (AIH) 特征的PBC患者中,将免疫抑制疗法添加到ursodeoxycholic acid (UDCA) 的益处尚不清楚.
研究的目的:
- 评估在患有PBC和自身免疫现象但不符合AIH特征的PBC标准的患者中,在UDCA中添加免疫抑制疗法的疗效.
主要方法:
- 一个回顾性-前性队列研究在三级医疗中心进行.
- 患有PBC和自身免疫现象的患者因IgG和/或转氨酶水平升高而被确定,不包括具有AIH特征的患者.
- 逆概率治疗权重 (IPTW) 用于平衡接受附加免疫抑制疗法与单一治疗的组之间的基线特征.
主要成果:
- 总共有652名患者被纳入,随访时间中位数为4.08年.
- 补充疗法组在一年后显示出显著更高的生化反应率 (49%对17%,p < 0.001).
- 补充疗法改善了转氨酶水平≥3x ULN或IgG水平≥1.3x ULN (p = 0.033) 的患者的无移植生存率.
结论:
- 补充免疫抑制疗法可能会增强PBC患者中转氨酶和IgG水平的正常化,而PBC水平则略微升高.
- 这种治疗方法似乎可以改善PBC患者的一个亚组的长期结果,这些患者的转氨酶或IgG水平明显升高.
相关概念视频
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
166
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
166
Autoimmune Disorders
442
Autoimmune diseases are a group of disorders in which the body's immune system mistakenly attacks its own cells, tissues, and organs. This results from an overactive immune response against substances and tissues normally present in the body. Let's delve into the concept and mechanism of autoimmune diseases from an immune system point of view, explore different causes and examples of such diseases, and discuss potential solutions.
Concept and Mechanism of Autoimmune Diseases
The immune...
Concept and Mechanism of Autoimmune Diseases
The immune...
442
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
139
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
139
Inflammatory Bowel Disease IV: Pharmacological Management
127
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
127
Chronic Bowel Disorders: Introduction
455
Chronic bowel diseases are a group of long-term conditions affecting the digestive tract, characterized by inflammation and damage to the gut lining. These conditions primarily include irritable bowel syndrome and inflammatory bowel disease.
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
455
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
120
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
120


